According to official proxy filings, James D. Taiclet, the Chairman, President, and CEO of Lockheed Martin Corporation, received a base salary of $1.75 million, accompanied by total annual compensation package value approaching $23.45 million when factoring in stock awards, performance incentives, and other compensation components.
Dr. Steven Nichtberger is the co-founder, President, and Chief Executive Officer of Cabaletta Bio.
Equity research analysts tracking Cabaletta Bio provide rolling 12-month consensus price targets based on clinical trial milestones, pipeline progress, and cash burn rates.
Compensation for an Associate Scientist position at biotechnology firms in major life science hubs like Philadelphia generally ranges from $85,000 to $115,000 annually, heavily influenced by individual educational background, direct laboratory experi...
Deciding whether Cabaletta Bio represents an appropriate addition depends on your appetite for clinical-stage biotechnology risk.
CABA stock exhibits high volatility, which is characteristic of clinical-stage biotechnology equities.
Morningstar and Zacks serve fundamentally different investment research styles.
Cabaletta Bio operates in the cutting-edge biotechnology sector focusing on cellular immunotherapy for autoimmune conditions, competing against other clinical-stage biopharmaceutical innovators and cellular therapy developers such as Kyverna Therapeu...
Cabaletta Bio focuses its clinical development programs on severe, treatment-resistant autoimmune diseases.
A major recent scientific breakthrough involves the use of engineered cell therapies—specifically chimeric antigen receptor T-cell (CAR-T) technology—to selectively deplete disease-causing B cells.
Cabaletta Bio is a publicly traded enterprise company listed on the NASDAQ exchange under the ticker symbol CABA.
No, a Zacks Rank #1 is not an automatic or guaranteed buy for every investor.
The CAR-T cell therapy landscape features several leading biopharmaceutical innovators ranging from large oncology giants like Novartis, Gilead (Kite Pharma), and Bristol Myers Squibb to specialized clinical-stage firms pioneering autoimmune applicat...
Cabaletta Bio officially became a publicly traded entity in October 2019, pricing its initial public offering (IPO) on the NASDAQ global market under the ticker symbol CABA to fund its clinical pipeline development.
Cabaletta Bio's board of directors is composed of experienced biotechnology executives, scientific founders, venture capital partners, and independent industry leaders who collectively oversee corporate governance, clinical development strategies, an...
Cabaletta Bio utilizes proprietary translational engineering platforms—such as its Cabaletta Approach to Selective Therapies (CAART)—designed to create targeted cellular immunotherapies that specifically bind and eliminate B cells producing disease-c...
Cabaletta Bio maintains its corporate headquarters and primary operational base in Philadelphia, Pennsylvania, placing it within a prominent East Coast hub for biotechnology research, academic medicine, and life sciences innovation.
The co-founder, President, and Chief Executive Officer of Cabaletta Bio is Dr.
Cabaletta Bio operates as a focused clinical-stage biopharmaceutical enterprise with a lean, specialized team typically numbering between 70 and 100 full-time employees dedicated to research, translational science, and clinical trial operations.
Retail and institutional investors can purchase shares of Cabaletta Bio through a standard brokerage account by trading under its official NASDAQ ticker symbol CABA.
Cabaletta Bio focuses primarily on developing targeted cellular immunotherapies for severe autoimmune diseases where traditional therapies are inadequate, targeting indications such as systemic lupus erythematosus (SLE), myositis, and generalized mya...
Cabaletta Bio (NASDAQ: CABA) is a clinical-stage biotechnology company focused on discovering and developing engineered T-cell therapies.
Cabaletta Bio stands out through its proprietary translational engineering platforms, such as the CAART strategy, which are designed to create targeted cellular immunotherapies.
Cabaletta Bio was founded in 2017 by academic pioneers and biotechnology entrepreneurs aiming to translate advanced cellular immunology discoveries into targeted, potentially curative treatments for patients suffering from severe autoimmune and B-cel...
Quantitative stock ranking platforms like Zacks periodically recalculate scores based on earnings-per-share estimate revisions.
In a corporate context, Cabaletta refers to Cabaletta Bio, a clinical-stage biotechnology company.